Abstract
Anginera is an epicardial patch developed on the basis of Dermagraft, another FDA-approved product. The underlying principle is that the fibroblasts are cells which can attach and stretch across spaces thus creating a human tissue. Retained in a natural matrix, fibroblasts can deliver grow factors and cytokines [1] which can promote angiogenesis and blood vessel maturation (Fig. 1). Indeed, it has been observed that, following the positioning of the patch on the injured cardiac tissue, new cardiac vascularisation is formed, with improved perfusion and indications of improvement of ventricular wall motion.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
